A new deal in HIV prevention: lessons from the global approach

We have now entered the second decade of the human immunodeficiency virus (HIV) pandemic. Medical science has responded to this new disease with remarkable dissection of the HIV virus and equally detailed descriptions of the clinical evolution of opportunistic infections and neoplasms in patients with the acquired immunodeficiency syndrome (AIDS). An entire industry has developed to address and improve strategies for the management of patients with HIV disease. Much of the funding for HIV research in the United States has focused on the development of vaccines [1] and antiviral therapy [2]. In essence, it was (and might still be) …